Our findings generalise to human HCC, where high expression of CYP2A6 correlates with increased median survival, as well as increased survival in the subset of patients that retain WT TP53 and maintain high expression of CYP2A6. These results suggest that increased CYP2A6 expression is an important component of p53’s tumour-suppressive function. The gene discussed is CYP2A6; the disease is neoplasm.